“Iron deficiency can contribute to increased or excessive hair shedding because low iron stores disrupt the hair growth cycle." (Instagram, @teawithmd, 2026-11-02. Video transcript adds: "iron deficiency can absolutely contribute to increased hair shedding... when your iron stores are low, that can disrupt your hair growth cycle and…”

The strongest retrieved evidence is a 2022 systematic review and meta-analysis. It searched PubMed, Scopus and Web of Science, entered 36 of 928 identified studies into a random-effects meta-analysis covering 10,029 participants, and found that women with nonscarring alopecia had lower ferritin values, mean difference -18.51 ng/dL (95% CI -25.85 to -11.16, p < 0.01). The authors framed the background as there being no clear-cut evidence in the existing literature of an association between iron deficiency and nonscarring alopecia, meaning this analysis was addressing an open question rather than confirming settled doctrine. The mechanism described in the post matches how the condition is defined in the literature. Telogen effluvium is a non-scarring form of diffuse hair loss characterised by premature transition of hair follicles into the telogen phase, resulting in excessive shedding, and iron deficiency reflected by low serum ferritin is considered a potential contributor to it in women. A 2025 cross-sectional study of 100 women reported that low serum ferritin levels are significantly associated with telogen effluvium in women, and serum ferritin may serve as a useful biomarker for identifying iron deficiency in patients presenting with diffuse hair loss. Important counter-evidence exists. A controlled study of 381 women at the Duke University Hair Disorders Clinic found that when ferritin at or below 15 ug/L was used as the definition, iron deficiency occurred in 12.4 percent of premenopausal women with female pattern hair loss, 12.1 percent with chronic telogen effluvium, and 29.8 percent of control subjects, that is, iron deficiency was more common in the controls than in the hair loss groups. At a ferritin threshold of 40 ug/L, iron deficiency occurred in 58.8 percent, 63.8 percent and 72.3 percent of those same premenopausal groups respectively. A post-COVID case-control study similarly reported that although serum ferritin was lower among telogen effluvium patients, it was still higher than the cutoff for diagnosing nonanemic iron deficiency, leading the authors to suggest it would not be a good biomarker in these cases. On treatment, the evidence is weaker than the association evidence. A review of vitamins and minerals in hair loss states that there is insufficient evidence on the efficacy of iron replacement on the outcome of telogen effluvium, although some benefits have been achieved in a few controlled studies, and notes of one trial that the study was too short and did not achieve the increase in ferritin levels necessary to treat iron-induced chronic telogen effluvium in women. On the workup, a clinical reference states that in chronic telogen effluvium iron deficiency is common in premenopausal women and evaluation of the complete blood count, serum iron, iron saturation and ferritin may be warranted, noting that the CBC may be completely normal in women with mild iron deficiency and hair loss, particularly women over 40. On the safety warning in the post, the NIH Office of Dietary Supplements states that dietary supplements containing iron carry a label warning that they should be kept out of the reach of children, and accidental overdose of iron-containing products is a leading cause of fatal poisoning in young children. Clinical reference material adds that excessive iron, whether acute or chronic, induces tissue injury and systemic toxicity, and acute toxicity often results from ingestion of iron supplements, particularly in paediatric populations. A Harvard summary notes that iron toxicity is rare because the body regulates absorption, and excessive iron occurs most often from taking high-dosage supplements. The speaker's stated credentials check out independently. A 2026 Marie Claire beauty awards profile describes Dr. Joyce Park as a board-certified dermatologist who practices through her clinic, Skin Refinery, and is known on social media as TeaWithMD, consistent with her first-party description as a board-certified dermatologist in Seattle.